

## **AGENDA**

***Uniform Formulary Beneficiary Advisory Panel (UF BAP)  
For August 2025, November 2025, Addendum to November 2025 (held  
January 16, 2026) and February 2026 Department of War Pharmacy and  
Therapeutics Committee Meetings  
June 23, 2026 at 10:00 AM Eastern Daylight Time***

### **Day #2 Meeting**

*The UF BAP meetings occurring on June 22-24, 2026, will include information presented at the DoW Pharmacy and Therapeutics (P&T) Committee meetings from February 2025, May 2025, Addendum to May 2025 held July 10, 2025, August 2025, November 2025, Addendum to November 2025 held January 16, 2026, February 2026 and May 2026. The information presented on June 22 (Day #1) will include the recommendations from the February 2025 (presented in the morning) and May 2025 and the July 10 Addendum (presented in the afternoon) P&T meetings. The information presented on June 23 (Day #2) will include the recommendations from August 2025 (presented in the morning) and November 2025, Addendum to November 2025 held January 16, 2026 and February 2026 (presented in the afternoon) P&T meetings. The information presented on June 24 (Day #3) will include the information presented at the May 2026 P&T meeting.*

### **Administrative Meeting 9:00 AM – 9:15 AM Eastern Daylight Time**

#### **Information from the August 2025 DoW P&T Meeting**

- **General session starts at 10:00 AM Eastern Daylight Time**
- **Roll Call**
- **Therapeutic Class Reviews**

*Members of the Defense Health Agency (DHA) Pharmacy Operations Division (POD) Formulary Management Branch (FMB) will present relative clinical and cost-effectiveness analyses along with the DoW P&T Committee recommendations for the Uniform Formulary (UF) and any recommended complete exclusion candidates.*

*The DoW P&T Committee made recommendations for the following drugs/drug classes during the August 2025 meeting.*

- **Drug Class Reviews**
  - *Atopy Agents: Interleukin (IL)-13 and IL-31 Subclasses*
  - *Diuretics: Mineralocorticoid Receptor Antagonists Subclass*
- **Newly Approved Drugs per 32 CFR 199.21(g)(5)**
  - *acetaminophen 325 mg/ibuprofen 97.5 mg tabs (Combogesic) – Pain Agents*
  - *acoltremon 0.003% (Tryptyr) – Ophthalmic Agent*
  - *atrasentan (Vanrafia) – Nephrology Agent for immunoglobulin A nephropathy*

(IgAN)

- *avutometinib with defactinib (Avmapki Fakzynja Co-pack) – Oncological Agent for low-grade serous ovarian cancer*
- *berdazimer (Zelsuvmi) – Anti-infective Agent for molluscum contagiosum*
- *chlorthalidone 12.5 mg tabs (Hemiclor) – Antihypertensive Agent*
- *efgartigimod alfa and hyaluronidase-qyfc (Vyvgart Hytrulo) – Neurological Agent for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy (CIDP)*
- *ensartinib (Ensacove) – Oncological Agent for non-small cell lung cancer (NSCLC)*
- *fitusiran (Qfitlia) – Antihemophilic Agent*
- *garadacimab-gxii (Andembry) – Corticosteroids-immune modulator for Hereditary Angioedema (HAE)*
- *hydrocortisone 1 mg/ml solution (Khindivi) – Corticosteroids-Immune Modulator*
- *insulin aspart-szjj (Merilog vial/pen) – Rapid Acting Insulin*
- *losartan 10 mg/mL oral suspension (Arbli) – Antihypertensive Agent*
- *meloxicam 20 mg/rizatriptan 10 mg (Symbravo) – Pain Agent*
- *nilotinib tartrate 50, 150, 200 mg capsules (nilotinib tartrate) – Oncological Agent for Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML)*
- *taletrectinib (Ibtrozi) – Oncological Agent for (NSCLC)*
- *terazosin 1 mg/ml solution (Tezruly) – Benign prostatic hyperplasia (BPH) Agent*
- *treprostinil inhalation powder (Yutrepia) – Pulmonary arterial Hypertension Agent*
- *ustekinumab-srlf (Imuldosa) – Targeted Immunomodulatory Biologics (TIBs) Interleukin (IL)-23s; biosimilar for Stelara*
- *ustekinumab (ustekinumab by Janssen) – TIBs IL-23s; unbranded Stelara*

➤ **Utilization Management Issues**

- **PA Criteria—Manual PA Criteria for Newly Approved Drugs Not Subject to 32 CFR 199.21(g)(5)**
  - *Antianxiety Agents—buspirone (Bucapsol)*
  - *Antihistamine-1: First Generation and Combos—clemastine (Clemasz)*
  - *Beta Blockers and Hydrochlorothiazide Combinations—bisoprolol 2.5 mg tablets*

- *Diabetes Non-Insulin: Biguanides—metformin 625 mg IR tablet*
- *Pain Agents: NSAIDs—diflunisal 375 mg tablets (Dolobid)*
- *Pain Agents: NSAIDs—flurbiprofen (Lurbipr)*
- **PA Criteria—Updated PA Criteria for New FDA-Approved Indications**
  - *Atopy—mepolizumab (Nucala)*
  - *Atopy: Oral JAK-1—upadacitinib (Rinvoq)*
  - *Endocrine Agents Miscellaneous—osilodrostat (Isturisa)*
  - *Hematological Agents—iptacopan (Fabhalta)*
  - *Immunosuppressives—belimumab (Benlysta)*
  - *Oncological Agents—belzutifan (Welireg)*
  - *Psoriasis Agents—roflumilast 0.3% foam (Zoryve)*
- **PA Criteria—Updated PA Criteria for Reasons Other Than New Indications**
  - *Gastrointestinal-1 Agent—budesonide oral suspension (Eohilia)*
  - *Hematological Agents: Platelets—avatrombopag (Doptelet)*
  - *Luteinizing Hormone Releasing Hormone (LHRH) Agonists-Antagonists—leuprolide acetate (Lutrate Depot)*
  - *Overactive Bladder Agents: Beta-3 Adrenergic Agonists*
    - *mirabegron (Myrbetriq)*
    - *vibegron (Gemtesa)*
  - *White Blood Cell Stimulants: Filgrastims—filgrastim-sndz (Zarxio)*
  - *Weight Loss Agents—semaglutide (Wegovy) and tirzepatide (Zepbound)*
- **Removal of PA Criteria**
  - *Cardiovascular Agents Miscellaneous—ivabradine (Corlanor)*
- **Removal of PA Criteria Prostate Cancer Agents: CYP-17 Inhibitors—abiraterone acetate (Zytiga)**
  - *abiraterone acetate 250 mg and 500 mg (Zytiga, generics)*
  - *abiraterone acetate micronized (Yonsa)*
- **Brand Over Generic Authorization and Tier 1 Copay**
  - *Pulmonary-2 Agents: umeclidinium/vilanterol inhaler (Anoro Ellipta)*

➤ **Panel Discussions**

*The UF BAP members will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will concur or non-concur on the recommendations of the DoW P&T Committee concerning the establishment of the UF and subsequent*

*recommended changes. The Panel will provide comments on their vote as directed by the Panel Chairman. Comments to the Director, DHA, or their designee will be considered before making a final UF decision.*

- **Break for Lunch 12:00 PM – 1:00 PM Eastern Daylight Time**

### **Information from the November 2025 DoW P&T Meeting**

- **General session starts at 1:00 PM Eastern Daylight Time**
- **Roll Call**
- **Therapeutic Class Reviews**

*Members of the DHA POD FMB will present relative clinical and cost-effectiveness analyses along with the DoW P&T Committee recommendations for the UF and any recommended complete exclusion candidates.*

*The DoW P&T Committee made recommendations for the following drugs/drug classes during the November 2025 meeting.*

- **Drug Class Reviews**

- *Metabolic Dysfunction Agents: Injectable Weight Loss Agents Subclass*
- *Metabolic Dysfunction Agents: Injectable Diabetic Agents Subclass*
- *Insulins: Rapid-Acting Insulins Subclass*

- **Newly Approved Drugs per 32 CFR 199.21(g)(5)**

- *brensocatib (Brinsupri) Pulmonary 1 Agent for Cystic Fibrosis bronchiectasis*
- *bumetanide nasal spray (Enbumyst) Diuretic*
- *dasatinib tablets (Phyrago) Oncological Agent for Chronic Myelogenous Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL)*
- *delgocitinib 2% cream (Anzupgo) – Atopy Agent for chronic hand eczema*
- *dihydroergotamine mesylate injection (Brekiya) – Migraine Agent*
- *donidalorsen injection (Dawnzera) – HAE - prophylaxis Agent*
- *dordaviprone (Modeyso) – Oncological Agent for glioma*
- *escitalopram 15 mg caps (no brand name) – Antidepressants and Non-Opioid Pain Syndrome Agents*
- *gepirone (Exxua) – Antidepressants and Non-Opioid Pain Syndrome Agents*
- *gepotidacin (Blujepa) – Antibiotic for urinary tract infections (UTI)*
- *imlunestrant (Inluriyo) – Oncological Agent for breast cancer*

- *lecanemab-irmb injection (Leqembi Iqlik) – Alzheimer’s Agents*
- *metoprolol tartrate 10 mg/mL oral solution (Lopressor) – Beta Blockers and Hydrochlorothiazide Combination Agents*
- *nalmefene injection (Zurnai) – Alcohol Deterrents-Narcotic Antagonists*
- *nitisinone (Harliku) – Miscellaneous Replacement Enzymes for alkaptonuria-associated urine homogentisic acid*
- *rilzabrutinib (Wayrilz) – Hematological Agents: Platelets, for thrombocytopenia*
- *sebetralstat (Ekterly) – Hereditary Angioedema (HAE)– Acute treatment*
- *sepiapterin oral powder (Sephience) – Miscellaneous Metabolic Agents for hyperphenylalaninemia in phenylketonuria*
- *sitagliptin 25 mg/mL oral solution (Brynovin) – Non-Inulin Diabetes Drugs – Dipeptidyl Peptidase-4 (DPP-4) inhibitor*
- *sulopenem etzadroxil /probenecid (Orlynvah) – Beta lactam Antibiotic for UTI*
- *zongertinib (Hernexeos) – Lung Cancer: Human Epidermal Growth Factor Receptor 2 (HER2) Agents*

➤ **Utilization Management Issues**

- **PA Criteria— Manual PA Criteria for Newly Approved Drugs Not Subject to 32 CFR 199.21(g)(5)**
  - *Antihistamine-1: First Generation and Combos—clemastine 2.68 mg tablets (Clemsza)*
  - *Anticholinergics-Antispasmodics—dicyclomine 40 mg tablets*
  - *Pain Agents: NSAIDs—flurbiprofen 100 mg tablets (Lurbiro)*
- **PA Criteria—Updated PA Criteria for New FDA-Approved Indications**
  - *Antihemophilic Agents: Non-Factor Agents—concizumab-mtci (Alhemo)*
  - *Hematological Agents—avatrombopag (Doptelet)*
  - *Migraine Agents: Calcitonin Gene-Related Peptide (CGRP) Preventive—fremanezumab (Ajovy)*
  - *Atopy—ruxolitinib 1.5% cream (Opzelura)*
  - *Targeted Immunomodulatory Biologics (TIBs): Non-Tumor Necrosis Factor (TNF) Inhibitors—apremilast (Otezla)*
  - *Oncological Agent: Poly ADP-Ribose Polymerase (PARP) Inhibitors—niraparib (Zejula)*
  - *Diabetes Non-Insulin Agents: Oral Glucagon-Like Peptide-1 Receptor Agonists—semaglutide (Rybelsus)*
  - *Hematological Agents—pegcetacoplan (Empaveli)*
- **PA Criteria—Updated PA Criteria for Reasons other than New FDA-**

## Approved Indications

- *Oncological Agents: Second Generation Antiandrogens—darolutamide (Nubeqa)*
- *Pulmonary Arteria Hypertension Agents—sotatercept (Winrevair)*

### • Removal of PA Criteria

- *Anti-Infectives: Anti-Helminthics—ivermectin (Stromectol, generics)*

### • Brand Over Generic Authorization and Tier 1 Copay

#### ▪ Additions

- *Oncological Agents: Chronic Myelogenous Leukemia—nilotinib (Tasigna)*

#### ▪ Removals

- *Anticoagulants: Oral Anticoagulants—dabigatran capsules (Pradaxa)*
- *Attention Deficit Hyperactivity Disorder (ADHD): Stimulants—lisdexamfetamine capsules (Vyvanse)*
- *Renin-Angiotensin Antihypertensives: Combinations—sacubitril/valsartan tablets (Entresto)*

### ➤ **Information from the Addendum to November 2025 DoW P&T Meeting held on January 16, 2026**

#### • **Therapeutic Class Reviews: Targeted Immunomodulatory Biologics (TIBs): Interleukin (IL-23) Inhibitors – Ustekinumab Formulations Formulary Status, PA Criteria and Implementation Plan**

- *The DoW P&T Committee held a virtual meeting on January 16, 2026 to determine the formulary status, PA criteria and implementation plan for the ustekinumab formulations.*

### ➤ **Panel Discussions**

*The UF BAP members will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will concur or non-concur on the recommendations of the DoW P&T Committee concerning the establishment of the UF and subsequent recommended changes. The Panel will provide comments on their vote as directed by the Panel Chairman. Comments to the Director, DHA, or their designee will be considered before making a final UF decision.*

### ➤ **Break 3:30 PM – 3:45 PM Eastern Daylight Time**

## **Information from the February 2026 DoW P&T Meeting**

➤ **General session starts at 3:45 PM Eastern Daylight Time**

➤ **Roll Call**

➤ **Therapeutic Class Reviews**

*Members of the Defense Health Agency (DHA) Pharmacy Operations Division (POD) Formulary Management Branch (FMB) will present relative clinical and cost-effectiveness analyses along with the DoW P&T Committee recommendations for the Uniform Formulary (UF) and any recommended complete exclusion candidates.*

*The DoW P&T Committee made recommendations for the following drugs/drug classes during the February 2026 meeting.*

➤ **Drug Class Reviews**

- *Targeted Immunomodulatory Biologics (TIBs): Interleukin (IL-23) Inhibitors Subclass: ustekinumab agents*
- *Oncological Agents: Myelofibrosis Subclass*

➤ **Newly Approved Drugs per 32 CFR 199.21(g)(5)**

- *celecoxib 10 mg/mL oral suspension (Vyscoxa) – Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)*
- *clonidine HCl oral solution 0.02 mg/mL (Javadin) – Anti-Hypertensive Agents*
- *cyclobenzaprine 2.8 SL tab (Tonmya) – Skeletal Muscle Relaxants*
- *elamipretide injection (Forzinity) – Miscellaneous Metabolic Agent for Barth Syndrome*
- *elinzanetant (Lynkuet) – Miscellaneous Gynecological Agent for Menopause*
- *furosemide 80 mg/mL SC injection (Lasix ONYU) – Diuretic*
- *mitapivat (Aqvesme) – Miscellaneous Metabolic Agents for Alpha or Beta Thalassemia*
- *nerandomilast (Jascayd) – Pulmonary I Agents: Idiopathic Pulmonary Fibrosis*
- *omidenepeg isopropyl 0.002% ophthalmic solution (Omlonti) – Glaucoma Agents*
- *paltusotine (Palsonify) – Miscellaneous Endocrine Agent for Acromegaly*
- *plozasiran injection (Redempro) – Antilipidemic 2 Agent for Familial Chylomicronemia Syndrome*
- *remibrutinib (Rhapsido) – Atopy Agent for Chronic Spontaneous Urticaria*
- *sevabertinib (Hyrnuo) – Lung Cancer: Human Epidermal Growth Factor Receptor 2 (HER2) Agents*

- *sibeprenlimab injection (Voyxact) – Miscellaneous Nephrology Agent for Immunoglobulin A (IgA) Nephropathy*
- *ziftomenib (Komzifti) – Acute Myeloid Leukemia (AML)*
- **Utilization Management Issues**
  - **PA New Criteria**
    - *Anticonvulsants-Antimania Agents—lamotrigine 10 mg/mL suspension (Subvenite)*
    - *Antipsychotic Agents: Atypical—cariprazine (Vraylar)*
  - **PA Criteria—Updated PA Criteria for New FDA-Approved Indications**
    - *Antipsychotic Agents: Atypical—lumateperone (Caplyta)*
    - *Atopy Agents—tezepelumab (Tezspire)*
    - *Corticosteroids-Immune Modulators: Hereditary Angioedema (HAE) Agents—berotralstat (Orladeyo)*
    - *Leukemia and Lymphoma Agents: Bruton Tyrosine Kinase Inhibitors (BTKIs)—pirtobrutinib (Jaypirca)*
    - *Oncological Agents—revumenib (Revuforj)*
    - *Psoriasis Agents—roflumilast 0.05% cream (Zoryve)*
    - *TIBs: Tumor Necrosis Factor (TNF) Inhibitors—golimumab (Simponi)*
    - *TIBs: Interleukin 23 (IL-23) inhibitors—guselkumab (Tremfya)*
    - *TIBs: Miscellaneous—tofacitinib (Xeljanz)*
  - **PA Criteria—Updated PA Criteria for Reasons Other Than New Indications**
    - *Antilipidemics-2 Agents—olezarsen (Tryngolza)*
    - *Antipsychotic Agents: Atypical—brexpiprazole (Rexulti)*
    - *Beta Blockers and Hydrochlorothiazide Combinations—bisoprolol 2.5 mg*
    - *Hematological Agents—avacopan (Tavneos)*
    - *Nephrology Agents Miscellaneous —sparsentan (Filspari)*
    - *Oncological Agents*
      - *Leukemia and Lymphoma Agents: AML —azacitidine (Onureg)*
      - *Multiple Myeloma—ixazomib (Ninlaro)*
      - *Oncological Agents—avapritinib (Ayvakit)*
      - *Oncological Agents: Lung Cancer—pralsetinib (Gavreto)*
      - *Oncological Agents: Lung Cancer—crizotinib (Xalkori)*
      - *Oncological Agents: Melanoma—cobimetinib (Cotellic)*

- *Oncological Agents: Non-BTKIs—duvelisib (Copiktra)*
- *Oncological Agents: Non-BTKIs—idelalisib (Zydelig)*
- *TIBs: TNF inhibitors—adalimumab (Humira and biosimilars)*
- **Brand Over Generic Authorization and Tier 1 Copay**
  - *Menopausal Hormone Therapy: Oral Single Agents—conjugated equine estrogen tablets (Premarin)*

➤ **Panel Discussions**

*The UF BAP members will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will concur or non-concur on the recommendations of the DoW P&T Committee concerning the establishment of the UF and subsequent recommended changes. The Panel will provide comments on their vote as directed by the Panel Chairman. Comments to the Director, DHA, or their designee will be considered before making a final UF decision.*

➤ **Adjournment**